{"id":175,"date":"2020-05-07T05:02:07","date_gmt":"2020-05-07T05:02:07","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=175"},"modified":"2020-05-14T05:09:17","modified_gmt":"2020-05-14T05:09:17","slug":"07-may-2020-hydroxychloroquine-no-significant-difference-between-hydroxychloroquine-and-standard-care","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/07-may-2020-hydroxychloroquine-no-significant-difference-between-hydroxychloroquine-and-standard-care\/","title":{"rendered":"(07 May 2020) Hydroxychloroquine- no significant difference between hydroxychloroquine and standard care"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"m-article-header__title f-h18\"><span class=\"title_default\">Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19<\/span><\/p>\n<p class=\"\">https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2012410<\/p>\n<p class=\"\">Of the 1376 patients, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days). Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation). In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2012410 Of the 1376 patients, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days). Overall, 346 patients (25.1%) had a&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/07-may-2020-hydroxychloroquine-no-significant-difference-between-hydroxychloroquine-and-standard-care\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(07 May 2020) Hydroxychloroquine- no significant difference between hydroxychloroquine and standard care&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,9],"tags":[10],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/175"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=175"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/175\/revisions"}],"predecessor-version":[{"id":176,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/175\/revisions\/176"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}